Pulmonx Statistics
Total Valuation
Pulmonx has a market cap or net worth of $280.55 million. The enterprise value is $204.64 million.
| Market Cap | 280.55M |
| Enterprise Value | 204.64M |
Important Dates
The next confirmed earnings date is Wednesday, May 1, 2024, after market close.
| Earnings Date | May 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pulmonx has 38.54 million shares outstanding. The number of shares has increased by 2.37% in one year.
| Shares Outstanding | 38.54M |
| Shares Change (YoY) | +2.37% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 4.68% |
| Owned by Institutions (%) | 92.92% |
| Float | 36.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.09 |
| Forward PS | 3.35 |
| PB Ratio | 2.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.50, with a Debt / Equity ratio of 0.35.
| Current Ratio | 6.50 |
| Quick Ratio | 5.59 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.65 |
Financial Efficiency
Return on equity (ROE) is -46.60% and return on invested capital (ROIC) is -38.77%.
| Return on Equity (ROE) | -46.60% |
| Return on Assets (ROA) | -32.10% |
| Return on Capital (ROIC) | -38.77% |
| Revenue Per Employee | $246,147 |
| Profits Per Employee | -$218,075 |
| Employee Count | 279 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 0.92 |
Taxes
In the past 12 months, Pulmonx has paid $571,000 in taxes.
| Income Tax | 571,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.72% in the last 52 weeks. The beta is 0.60, so Pulmonx's price volatility has been lower than the market average.
| Beta (1Y) | 0.60 |
| 52-Week Price Change | -37.72% |
| 50-Day Moving Average | 9.16 |
| 200-Day Moving Average | 10.84 |
| Relative Strength Index (RSI) | 30.01 |
| Average Volume (30 Days) | 578,503 |
Short Selling Information
The latest short interest is 1.73 million, so 4.48% of the outstanding shares have been sold short.
| Short Interest | 1.73M |
| Short Previous Month | 1.13M |
| Short % of Shares Out | 4.48% |
| Short % of Float | 4.67% |
| Short Ratio (days to cover) | 2.57 |
Income Statement
In the last 12 months, Pulmonx had revenue of $68.68 million and -$60.84 million in losses. Loss per share was -$1.60.
| Revenue | 68.68M |
| Gross Profit | 50.75M |
| Operating Income | -61.94M |
| Pretax Income | -60.27M |
| Net Income | -60.84M |
| EBITDA | -52.81M |
| EBIT | -57.04M |
| Loss Per Share | -$1.60 |
Balance Sheet
The company has $117.34 million in cash and $41.42 million in debt, giving a net cash position of $75.92 million or $1.97 per share.
| Cash & Cash Equivalents | 117.34M |
| Total Debt | 41.42M |
| Net Cash | 75.92M |
| Net Cash Per Share | $1.97 |
| Equity / Book Value | 118.32M |
| Book Value Per Share | 3.07 |
| Working Capital | 127.27M |
Cash Flow
In the last 12 months, operating cash flow was -$37.61 million and capital expenditures -$807,000, giving a free cash flow of -$38.42 million.
| Operating Cash Flow | -37.61M |
| Capital Expenditures | -807,000 |
| Free Cash Flow | -38.42M |
| FCF Per Share | -$1.01 |
Margins
Gross margin is 73.90%, with operating and profit margins of -90.19% and -88.60%.
| Gross Margin | 73.90% |
| Operating Margin | -90.19% |
| Pretax Margin | -87.76% |
| Profit Margin | -88.60% |
| EBITDA Margin | -76.89% |
| EBIT Margin | -83.06% |
| FCF Margin | -55.94% |
Dividends & Yields
Pulmonx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.37% |
| Shareholder Yield | -2.37% |
| Earnings Yield | -21.69% |
| FCF Yield | -13.69% |
Analyst Forecast
The average price target for Pulmonx is $15.57, which is 113.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.57 |
| Price Target Difference | 113.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 21.49% |
| EPS Growth Forecast (5Y) | -16.30% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pulmonx has an Altman Z-Score of -0.22 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.22 |
| Piotroski F-Score | 2 |